Funds holding “VRTX”
Which closed-end funds own a security? Searches the latest N-PORT snapshot of every active fund. Enter a ticker (issuer-level: matches the vendor-mapped ticker), a CUSIP or ISIN (security-level: one specific bond or share class), or part of a name.
16 positions across 16 funds. Weights are percent of net assets from each fund’s latest N-PORT; report dates differ by fund.
| Fund | Position | Identifier | Type | Weight | Value (USD) | Report date | Coverage |
|---|---|---|---|---|---|---|---|
| BME BlackRock Health Sciences Trust Healthcare | Vertex Pharmaceuticals Inc | 92532F100 | EC | 2.77% | $15.9M | Jun 30, 2026 | full (152 positions) |
| BMEZ BlackRock Health Sciences Term Trust Healthcare | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.96% | $10.4M | Jun 30, 2026 | full (170 positions) |
| ADX Adams Diversified Equity Fund U.S. Equity | Vertex Pharmaceuticals Incorporated | 92532F100 | EC | 0.71% | $23.5M | Jun 30, 2026 | full (108 positions) |
| GRX Gabelli Healthcare & WellnessRx Trust Healthcare | VERTEX PHARMACEUTICALS INC | 92532F100 | EC | 0.70% | $1.6M | Jun 30, 2026 | full (195 positions) |
| USA Liberty All Star Equity Fund U.S. Equity | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.60% | $12.2M | Jun 30, 2026 | full (148 positions) |
| ECAT BlackRock ESG Capital Allocation Term Trust U.S. Equity | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.41% | $6.9M | Jun 30, 2026 | full (1,193 positions) |
| CLM Cornerstone Strategic Investment Fund Multi-Asset | VERTEX PHARMACEUTICALS INC | 92532F100 | EC | 0.40% | $8M | Jun 30, 2026 | full (113 positions) |
| CRF Cornerstone Total Return Fund Multi-Asset | VERTEX PHARMACEUTICALS INC | 92532F100 | EC | 0.40% | $4.3M | Jun 30, 2026 | full (101 positions) |
| CSQ Calamos Strategic Total Return Fund Multi-Asset | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.29% | $14.1M | Jul 31, 2026 | full (820 positions) |
| HQL abrdn Life Sciences Investors Healthcare | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.27% | $1.9M | Jun 30, 2026 | full (145 positions) |
| TY Tri-Continental Corp U.S. Equity | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.25% | $5.2M | Jun 30, 2026 | full (240 positions) |
| BCAT BlackRock Capital Allocation Term Trust U.S. Equity | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.25% | $4.2M | Jun 30, 2026 | full (1,148 positions) |
| HQH abrdn Healthcare Investors Healthcare | Vertex Pharmaceuticals Inc | 92532F100 | EC | 0.25% | $3.4M | Jun 30, 2026 | full (154 positions) |
| GDV Gabelli Dividend & Income Trust U.S. Equity | VERTEX PHARMACEUTICALS INC | 92532F100 | EC | 0.06% | $2M | Jun 30, 2026 | full (729 positions) |
| GOF Guggenheim Strategic Opportunities Fund Multi-Asset | VERTEX PHARMACEUTICALS INC | 92532F100 | EC | 0.00% | $16.6K | May 29, 2026 | full (1,841 positions) |
| BRW Saba Capital Income & Opportunities Fund U.S. Equity | Vertex Pharmaceuticals Inc | 92532F100 | EC | -0.05% | $-163K | Jul 31, 2026 | full (1,143 positions) |
Matching position names
Vertex Pharmaceuticals Inc · 10VERTEX PHARMACEUTICALS INC · 5Vertex Pharmaceuticals Incorporated · 1
Historical holdings reports are not a real-time portfolio. Security-level matching (CUSIP/ISIN) distinguishes a company’s bonds, common shares, preferreds and derivatives; issuer-level matching groups them by name or ticker and is labelled as such. See the overlap tool to compare two portfolios.